AASLD Releases Statement on HCV Guidance
AASLD has issued a statement which explains the purpose and methods of the HCV Guidance project and includes a set of Frequently Asked Questions (FAQs). This project is a joint effort of AASLD and the IDSA, in collaboration with the IAS-USA.
NEW! The HCV Guidance now includes information on When and In Whom To Initiate HCV Therapy.
NEW! Vertex removing Telaprevir from US market
Vertex Pharmaceuticals Incorporated will discontinue the sale and distribution of INCIVEK® (telaprevir) in the United States by October 2014.
Patients should talk to their health care providers if they are currently receiving INCIVEK or were planning to start INCIVEK soon. Patients should not stop taking INCIVEK unless they have been instructed by their health care provider. Vertex will continue to provide financial support to eligible patients currently prescribed INCIVEK.
For INCIVEK product support information, please contact 1-877-824-4281.
General Registration and Housing for The Liver Meeting® Now Open
General Advance Registration and Housing are now open for The Liver Meeting®. Register today and save.
Also, view the Program and Registration Guide.
NEW! Become a Member of AASLD
AASLD's membership comprises ALL professionals dedicated to hepatobiliary discoveries and patient care. Member benefits include access to: LiverLearning, member directory, and Special Interest Groups. So what are you waiting for? Join today.
Practice Guideline: Hepatic Encephalopathy in Chronic Liver Disease
AASLD announces the release of a new practice guideline on Hepatic Encephalopathy. This practice guideline was developed in collaboration with EASL.